Orphazyme to present at the Gordon Research Conference on Lysosomal Diseases 15-19 March in Galveston, TX
Thomas Kirkegaard, CSO, will present results from Orphazyme’s lead program for lysosomal storage diseases, arimoclomol, at the prestigious Gordon Research Conference on Lysosomal Diseases, taking place in Galveston, TX, USA on 15.-19. March. Arimoclomol, a phase II enabled, orally available small molecule, is entering into clinical trials in Niemann-Pick type C and the presentation will cover data from animal pharmacological models of the disease as well as an overview of the accompanying clinical development plans.
"We are proud to present our latest results that offer important new insights into the potential of our lead clinical program”, says CSO Thomas Kirkegaard. “We are committed to our mission of bringing novel therapeutic opportunities to people suffering from lysosomal storage diseases.”
At the Gordon Research Conference Orphazyme will be represented by Thomas Kirkegaard (Orphazyme CSO), Professor Marja Jaattela (Danish Cancer Society and Orphazyme co-founder) as well as James Gray (University of Oxford).